Blocking Mammalian Target of Rapamycin Alleviates Bone Cancer Pain and Morphine Toleranceviaµ-Opioid Receptor

International Journal of Cancer - United States
doi 10.1002/ijc.29927
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Neuron-Restrictive Silencer Factor–mediated Downregulation of Μ-Opioid Receptor Contributes to the Reduced Morphine Analgesia in Bone Cancer Pain

Pain
NeurologyAnesthesiologyPain MedicinePharmacology
2017English

Effects of Intraperitoneal and Intrathecal Morphine Analgesia on the Expression of Μ-Opioid Receptors in Bone Cancer Pain Rats

Dose-Response
Chemical HealthMutagenesisPublic HealthEnvironmentalSafetyToxicologyHealthOccupational Health
2019English

Mammalian Target of Rapamycin (mTOR; FRAP; RAFT1)

Science-Business eXchange
2010English

Mammalian Target of Rapamycin: A Target for (Lung) Diseases and Aging

Annals of the American Thoracic Society
PulmonaryRespiratory Medicine
2016English

Temsirolimus, an Inhibitor of Mammalian Target of Rapamycin

Clinical Cancer Research
Cancer ResearchOncology
2008English

A Kappa Opioid Receptor Agonist Blocks Bone Cancer Pain Without Altering Bone Loss, Tumor Size, or Cancer Cell Proliferation in a Mouse Model of Cancer-Induced Bone Pain

Journal of Pain
NeurologyAnesthesiologyPain Medicine
2018English

Targeted Inhibition of Mammalian Target of Rapamycin Signaling Inhibits Tumorigenesis of Colorectal Cancer

Clinical Cancer Research
Cancer ResearchOncology
2009English

Metformin Inhibits Mammalian Target of Rapamycin Dependent Translation Initiation in Breast Cancer Cells

Cancer Research
Cancer ResearchOncology
2007English

New Targets for Therapy in Breast Cancer: Mammalian Target of Rapamycin (mTOR) Antagonists

Breast Cancer Research
Cancer ResearchOncology
2004English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy